Understanding and targeting alkylator resistance in glioblastoma

Cancer Discovery

Volumn 4, Issue 10, 2014, Pages 1120-1122

  Wick, Wolfgang ^a   Platten, Michael ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ATM PROTEIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; DNA GLYCOSYLTRANSFERASE;

ARTICLE; DNA DAMAGE; DRUG EFFICACY; DRUG RESPONSE; GENE EXPRESSION; GERMLINE MUTATION; GLIOBLASTOMA; HISTONE ACETYLATION; HUMAN; POLYMERIZATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; ANIMAL; DRUG RESISTANCE; METABOLISM;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; ATAXIA TELANGIECTASIA MUTATED PROTEINS; DNA GLYCOSYLASES; DRUG RESISTANCE, NEOPLASM; HUMANS;

EID: 84907559839     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-14-0918     Document Type: Article

References (13)

1. Wick W, Weller M, van den Bent M, Sanson M, Weiler M, von Deimling A, et al. MGMT testing—the challenges for biomarker-based glioma treatment. Nat Rev Neurol 2014; 10: 372-85
2. Nakagawachi T, Soejima H, Urano T, Zhao W, Higashimoto K, Satoh Y, et al. Silencing effect of CpG island hypermethylation and histone modifi cations on O6-methylguanine-DNA methyltransferase (MGMT) gene expression in human cancer. Oncogene 2003; 22: 8835-44
3. Zhao W, Soejima H, Higashimoto K, Nakagawachi T, Urano T, Kudo S, et al. The essential role of histone H3 Lys9 di-methylation and MeCP2 binding in MGMT silencing with poor DNA methylation of the promoter CpG island. J Biochem 2005; 137: 431-40
4. Kitange GJ, Mladek AC, Carlson BL, Schroeder MA, Pokorny JL, Cen L, et al. Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts. Clin Cancer Res 2012; 18: 4070-9
5. Weiler M, Blaes J, Pusch S, Sahm F, Czabanka M, Luger S, et al. The mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. Proc Natl Acad Sci USA 2014; 111: 409-14
6. Sturm D, Witt H, Hovestadt V, Khuong-Quang D-A, Jones DTW, Konermann C, et al. Hotspot mutations in H3F3A and IDH1 defi ne distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 2012; 22: 425-37
7. Wiestler B, Claus R, Hartlieb SA, Schliesser MG, Weiss EK, Hielscher T, et al. Malignant gliomas of elderly patients have a distinct molecular profi le: an analysis of the NOA-08 study collective. Neurooncol 2013; 15: 1017-26
8. Sarkaria JN, Kitange GJ, James CD, Plummer R, Calvert H, Weller M, et al. Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin Cancer Res 2008; 14: 2900-8
9. Agnihotri S, Burrell K, Buczkowicz P, Remke M, Golbourn B, Chornenkyy Y, et al. ATM regulates 3-methylpurine-DNA glycosylase and promotes therapeutic resistance to alkylating agents. Cancer Discov 2014; 4: 1198–1213
10. Vecchio D, Daga A, Carra E, Marubbi D, Raso A, Mascelli S, et al. Pharmacokinetics, pharmacodynamics and effi cacy on pediatric tumors of the glioma radiosensitizer KU60019. Int J Cancer 2014 Aug 4. [Epub ahead of print].
11. Gil del Alcazar CR, Hardebeck MC, Mukherjee B, Tomimatsu N, Gao X, Yan J, et al. Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma. Clin Cancer Res 2014; 20: 1235-48
12. Batista LF, Roos WP, Christmann M, Menck CF, Kaina B. Differential sensitivity of malignant glioma cells to methylating and chloroethylating anticancer drugs: p53 determines the switch by regulating xpc, ddb2, and DNA double-strand breaks. Cancer Res 2007; 67: 11886-95
13. Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 2014; 344: 1396-401.